抗血小板新药vorapaxar

被引：7

作者：

李春杏

朱珠

机构：

[1] 中国医学科学院中国协和医科大学北京协和医院药剂科

来源：

中国新药杂志 | 2015年 / 06期

关键词：

沃拉帕沙; 抗血小板药; 血栓事件; 安全性;

D O I：

暂无

中图分类号：

R973 [血液和造血系统药物];

学科分类号：

1007 ;

摘要：

凝血酶受体拮抗剂vorapaxar(沃拉帕沙)为新一类抗血小板药,2014年5月8日美国食品与药品监督管理局(FDA)批准其硫酸盐(商品名:Zontivity)上市,与标准抗血小板治疗药合用作为急性冠脉综合征的二级预防,可改善心梗患者血栓性心血管事件。该药在发挥疗效的同时也需关注出血的风险。文中对其药理作用、临床研究和安全性等做一综述。

引用

页码：601 / 604+643 +643

页数：5

共 10 条

[1]

PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact[J] . Heather M. Judge,Lisa K. Jennings,David J. Moliterno,Edward Hord,Rosemary Ecob,Pierluigi Tricoci,Tyrus Rorick,Jayaprakash Kotha,Robert F. Storey. Platelets . 2014 (3)

[2] Emerging antithrombotic drugs for acute coronary syndrome [J].

Shimada, Yuichi J. ;

Giugliano, Robert P. .

EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (03) :307-318

[3] The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar [J].

Kosoglou, Teddy ;

Statkevich, Paul ;

Kumar, Bharath ;

Xuan, Fengjuan ;

Schiller, James E. ;

Johnson-Levonas, Amy O. ;

Young, Sophia ;

Cutler, David L. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (05) :540-549

[4] Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment [J].

Statkevich, Paul ;

Kosoglou, Teddy ;

Preston, Richard A. ;

Kumar, Bharath ;

Xuan, Fengjuan ;

Trusley, Craig ;

Schiller, James E. ;

Langdon, Ronald B. ;

Cutler, David L. .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (11) :1501-1508

[5]

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial[J] . Benjamin M Scirica,Marc P Bonaca,Eugene Braunwald,Gaetano M De Ferrari,Daniel Isaza,Basil S Lewis,Felix Mehrhof,Piera A Merlini,Sabina A Murphy,Marc S Sabatine,Michal Tendera,Frans Van de Werf,Robert Wilcox,David A Morrow. The Lancet . 2012 (9850)

[6] Safety of the Novel Protease-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with a History of Ischemic Stroke [J].

Shinohara, Yukito ;

Goto, Shinya ;

Doi, Masaki ;

Jensen, Peder .

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2012, 21 (04) :318-324

[7] Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects [J].

Kosoglou, Teddy ;

Reyderman, Larisa ;

Tiessen, Renger G. ;

van Vliet, Andre A. ;

Fales, Robert R. ;

Keller, Robert ;

Yang, Bo ;

Cutler, David L. .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (03) :249-258

[8]

SCH 530348: a novel oral thrombin receptor antagonist[J] . Marc P Bonaca,David A Morrow. Future Cardiol. . 2009 (5)

[9]

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study[J] . Richard C Becker,David J Moliterno,Lisa K Jennings,Karen S Pieper,Jinglan Pei,Alan Niederman,Khaled M Ziada,Gail Berman,John Strony,Diane Joseph,Kenneth W Mahaffey,Frans Van de Werf,Enrico Veltri,Robert A Harrington. The Lancet . 2009 (9667)

[10]

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial[J] . David A. Morrow,Benjamin M. Scirica,Keith A.A. Fox,Gail Berman,John Strony,Enrico Veltri,Marc P. Bonaca,Polly Fish,Carolyn H. McCabe,Eugene Braunwald. American Heart Journal . 2009 (3)

← 1 →